Pneumococcal protein vaccines – affordability, availability and use in developing countries

Dr Mark Alderson, Director, Pneumococcal Vaccine Project, Vaccine Development Global Program at PATH, discussed the progress on pneumococcal protein vaccines – affordability, availability and use in developing countries.

Watch his presentation from the 10th annual World Vaccine Congress Washington now for free.

Topics discussed:

• Developing a portfolio of potential vaccine candidates with a particular emphasis on “common protein” vaccines – common to all pneumococcal serotypes
• Current protein vaccine partnerships range from novel methods of antigen discovery to well characterized vaccine candidates that have provided protection in multiple animal models and early stages of clinical evaluation
• Second strategy involves development of a killed, whole cell vaccine, also designed to offer broad serotype-independent coverage coupled with low manufacturing costs and ease of administration.
• Exploring strategies to incorporate common protein antigens into a limited valency pneumococcal conjugate vaccine (PCV)
• Advantages to the regulatory path established for licensure of new PCVs and offering further benefit of broader coverage by adding a pneumococcal protein antigen

For more updates on the vaccines industry, follow us on Twitter:  @vaccinenation or join our LinkedIn group: Vaccine Nation